Business Wire

CA-VERIMATRIX

20.4.2022 17:47:11 CEST | Business Wire | Press release

Share
Mexico’s Megacable Selects Verimatrix Streamkeeper and XTD Products To Further Strengthen Security

Regulatory News:

Verimatrix , (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Megacable , one of Mexico’s largest telecommunications companies, selected a suite of Verimatrix products and technologies to fortify its enterprise defenses; Verimatrix XTD (Extended Threat Defense), Streamkeeper Watermarking , Streamkeeper Edge Authenticator and App Shield .

Megacable, the first company in Mexico to offer quadruple-play services (cable television, broadband internet, fixed telephony and mobile telephony), has millions of subscribers using the media company’s apps running on unmanaged devices. The company was well aware that extended endpoints at the app level could be weaponized at any time by attackers to attack their enterprise defenses, and they wanted to find a way to expand their defense beyond the traditional perimeter. Additionally, it’s no secret that the media & entertainment industry is seeing a rise in industrial-scale piracy attacks on content distribution networks, and they selected Verimatrix specifically for its distinguished reputation in both threat defense and anti-piracy.

Megacable products set to use Verimatrix threat defense and anti-piracy solutions include the Xview+ app, Android TV set-top boxes, select Megacable.com.mx payment/financial services, as well as other internal Megacable apps.

Hackers are continually looking for new ways to infiltrate enterprise security walls and Verimatrix XTD consistently identifies and closes vulnerabilities. Verimatrix XTD is an enterprise SaaS solution that will monitor Megacable’s mobile apps and devices connected to their cloud services.

Verimatrix XTD’s features include:

  • Shielding Apps – With self-defending mobile application shielding, Verimatrix provides organizations with layers of protections such as obfuscation, environmental checks​ and anti-tamper, plus 24/7 monitoring with immediate detection when an app is under attack with remote shut-down capability.
  • Unmanaged Device Telemetry – Protection from unmanaged devices at the endpoint, such as set-top box receivers, IoT and medical devices, by gaining real-time, continuous threat intelligence utilizing Verimatrix’s zero-code telemetry technology.
  • Monitoring and Early Detection – Better understand the threat profile of your installed base of users, and drill down into the risk score of an individual app instance, with real-time notifications of high-risk events to uncover hidden dangers in your enterprise security wall.
  • Attack Pattern Detection and Prediction – Comprehensive, predictive analysis of cyber threats based on large data sets, artificial intelligence (AI) and machine learning (ML), to recognize patterns, making future predictions to benefit the enterprise.

Having used Verimatrix IPTV and DVB Hybrid content security solutions since 2012, Megacable’s work with Verimatrix is also expanded with the deployment of Watermarking and Edge Authenticator anti-piracy solutions. The unique deployment of Streamkeeper zero-code injection technology into select Megacable set-top boxes is a first for both companies. The process will protect access to the Content Security Network (CDN) without the need for cumbersome, time consuming or expensive integrations, meeting stringent requirements from major studios that require it for 4K Ultra HD content. Megacable may add additional Verimatrix Streamkeeper services to its portfolio of anti-piracy countermeasures in the future.
“Megacable already enjoys robust network security, but by adding Verimatrix XTD and Streamkeeper anti-piracy technologies, we’re creating an even more formible security posture for our company, our content and our customers,” said Gerardo Seifert Arriola, Chief Marketing Officer at Megacable. “We’re pleased to continue working with Verimatrix to provide an excellent user experience while also deploying the latest in security technology to maintain our stance as the regional leader in our industry.”

“Megacable has taken a bold step forward by adding threat defense and anti-piracy technology to their enterprise security stack,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “Megacable is now our largest customer to date to commit to deploying Verimatrix Streamkeeper and Verimatrix XTD solutions. The alliance underscores our goal to provide proactive cybersecurity and anti-piracy countermeasures that fortify operators against threats of today and the unforeseen dangers of tomorrow. We’re pleased to continue working with Megacable to provide unique and innovative solutions that boost protections and also help ensure exceptional user experiences no matter how content is accessed.”

About Megacable
Megacable Holdings S.A.B. de C.V. (BMV: MEGA.CPO) is one of the largest telecommunications companies in Mexico and Latin America. It carries out operations in 28 states of the country, with a presence in 400 locations. As of December 31, 2021, it has about 4.2 million unique subscribers, including more than 3.8 million internet subscribers, more than 3.5 million video users and more than 3 million fixed telephony customers. It offers its services through a network of nearly 66,000 kilometers, covering more than 9.5 million homes. Visit www.megacable.com.mx .

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye